Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study

References (28)

1. Wilkinson ST, Sanacora G. Considerations on the off-label use of ketamine as a treatment for mood disorders. JAMA. 2017;318(9):793–794. PubMed CrossRef
2. Wilkinson ST, Toprak M, Turner MS, et al. A survey of the clinical, off-label use of ketamine as a treatment for psychiatric disorders. Am J Psychiatry. 2017;174(7):695–696. PubMed CrossRef
3. Skånland SS, Cieślar-Pobuda A. Off-label uses of drugs for depression. Eur J Pharmacol. 2019;865:172732. PubMed CrossRef
4. Cosci F, Fava GA. When anxiety and depression coexist: the role of differential diagnosis using clinimetric criteria. Psychother Psychosom. 2021;90(5):308–317. PubMed CrossRef
5. Smith WT, Londborg PD, Glaudin V, et al. Short-term augmentation of fluoxetine with clonazepam in the treatment of depression: a double-blind study. Am J Psychiatry. 1998;155(10):1339–1345. PubMed CrossRef
6. Papakostas GI, Clain A, Ameral VE, et al. Fluoxetine-clonazepam cotherapy for anxious depression: an exploratory, post-hoc analysis of a randomized, double blind study. Int Clin Psychopharmacol. 2010;25(1):17–21. PubMed CrossRef
7. Bushnell GA, Stürmer T, Gaynes BN, et al. Simultaneous antidepressant and benzodiazepine new use and subsequent long-term benzodiazepine use in adults with depression, United States, 2001–2014. JAMA Psychiatry. 2017;74(7):747–755. PubMed CrossRef
8. Diekamp B, Borentain S, Fu DJ, et al. Effect of concomitant benzodiazepine use on efficacy and safety of esketamine nasal spray in patients with major depressive disorder and acute suicidal ideation or behavior: pooled randomized, controlled trials. Neuropsychiatr Dis Treat. 2021;17:2347–2357. PubMed CrossRef
9. Shiroma PR, Thuras P, Wels J, et al. A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression. Transl Psychiatry. 2020;10(1):206. PubMed CrossRef
10. Albott CS, Shiroma PR, Cullen KR, et al. The antidepressant effect of repeat dose intravenous ketamine is delayed by concurrent benzodiazepine use. J Clin Psychiatry. 2017;78(3):e308–e309. PubMed CrossRef
11. Andrashko V, Novak T, Brunovsky M, et al. The antidepressant effect of ketamine is dampened by concomitant benzodiazepine medication. Front Psychiatry. 2020;11:844. PubMed CrossRef
12. Frye MA, Blier P, Tye SJ. Concomitant benzodiazepine use attenuates ketamine response: implications for large scale study design and clinical development. J Clin Psychopharmacol. 2015;35(3):334–336. PubMed CrossRef
13. Ford N, Ludbrook G, Galletly C. Benzodiazepines may reduce the effectiveness of ketamine in the treatment of depression. Aust N Z J Psychiatry. 2015;49(12):1227. PubMed CrossRef
14. Fava M, Freeman MP, Flynn M, et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020;25(7):1592–1603. PubMed CrossRef
15. Salloum NC, Fava M, Freeman MP, et al. Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. Depress Anxiety. 2019;36(3):235–243. PubMed CrossRef
16. Ionescu DF, Luckenbaugh DA, Niciu MJ, et al. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. J Clin Psychiatry. 2014;75(9):e932–e938. PubMed CrossRef
17. Castellano D, Shepard RD, Lu W. Looking for novelty in an “old” receptor: recent advances toward our understanding of GABA_ARs and their implications in receptor pharmacology. Front Neurosci. 2021;14:616298. PubMed CrossRef
18. Balon R, Starcevic V. Role of benzodiazepines in anxiety disorders. Adv Exp Med Biol. 2020;1191:367–388. PubMed CrossRef
19. Strasburger SE, Bhimani PM, Kaabe JH, et al. What is the mechanism of Ketamine’s rapid-onset antidepressant effect? a concise overview of the surprisingly large number of possibilities. J Clin Pharm Ther. 2017;42(2):147–154. PubMed CrossRef
20. Irwin MN, VandenBerg A. Retracing our steps to understand ketamine in depression: a focused review of hypothesized mechanisms of action. Ment Health Clin. 2021;11(3):200–210. PubMed CrossRef
21. Veraart JKE, Smith-Apeldoorn SY, Bakker IM, et al. Pharmacodynamic interactions between ketamine and psychiatric medications used in the treatment of depression: a systematic review. Int J Neuropsychopharmacol. 2021;24(10):808–831. PubMed CrossRef
22. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134(4):382–389. PubMed CrossRef
23. Hamilton M. A rating scale for depression. 1960;23(1):56–65.
24. Bech P, Allerup P, Gram LF, et al. The Hamilton Depression Scale: evaluation of objectivity using logistic models. Acta Psychiatr Scand. 1981;63(3):290–299. PubMed CrossRef
25. Carrozzino D, Patierno C, Fava GA, et al. The Hamilton Rating Scales for depression: a critical review of clinimetric properties of different versions. Psychother Psychosom. 2020;89(3):133–150. PubMed CrossRef
26. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville: US Department of Health, Education, and Welfare; Public Health Service; Alcohol, Drug Abuse, and Mental Health Administration; 1976.
27. Chandler GM, Iosifescu DV, Pollack MH, et al. RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). CNS Neurosci Ther. 2010;16(5):322–325. PubMed CrossRef
28. Feaster DJ, Mikulich-Gilbertson S, Brincks AM. Modeling site effects in the design and analysis of multi-site trials. Am J Drug Alcohol Abuse. 2011;37(5):383–391. PubMed CrossRef